# Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

> **NCT06712030** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Puerta de Hierro University Hospital** · enrollment: 114 (estimated)

## Conditions studied

- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

## Interventions

- **DRUG:** Sacubitril / Valsartan

## Key facts

- **NCT ID:** NCT06712030
- **Lead sponsor:** Puerta de Hierro University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2027-04
- **Final completion:** 2027-06
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712030, "Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06712030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*